| Literature DB >> 28236498 |
Santiago Moreno1, Antonio Antela2, Felipe García3, Julia Del Amo4, Vicente Boix5, Pep Coll6, Claudia Fortuny7, Juan L Gómez Sirvent8, Félix Gutiérrez9, José A Iribarren10, Josep M Llibre11, Juan C López Bernaldo de Quirós12, Juan Emilio Losa13, Ana Lozano14, Michael Meulbroek15, Julián Olalla16, Ferran Pujol15, Federico Pulido17, Manuel Crespo Casal18, Juan González García19, José López Aldeguer20, Jose A Pérez Molina21, Daniel Podzamczer Palter22, Antonio Rivero Román23.
Abstract
Administration of antiretroviral drugs to individuals exposed to, but not infected by, HIV has been shown to reduce the risk of transmission. The efficacy of pre-exposure prophylaxis (PrEP) makes it obligatory to include it in an integral program of prevention of HIV transmission, together with other measures, such as use of the condom, training, counseling, and appropriate treatment of infected individuals. In this document, the AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica [SEIMC]) provides its views on this important subject. The available evidence on the usefulness of PrEP in the prevention of transmission of HIV is presented, and the components that should make up a PrEP program and whose development and implementation are feasible in Spain are set out.Entities:
Keywords: HIV infection; Infección por VIH; Pre-exposure prophylaxis; Prevención; Prevention; Profilaxis pre-exposición; Tenofovir
Mesh：
Substances：
Year: 2017 PMID： 28236498 DOI： 10.1016/j.eimc.2016.11.016
Source DB: PubMed Journal: Enferm Infecc Microbiol Clin ISSN： 0213-005X Impact factor: 1.731